May 2021
Professor Karl Lewis about cemiplimab in patients with metastatic basal cell carcinoma
Prof. Karl Lewis, Medical Oncology, University of Colorado Hospital, Aurora, CO, USA
In this episode, Prof. Lewis talks us through the results of an interim analysis of a phase II study that studies the potential of cemiplimab in patients with metastatic basal cell carcinoma who progressed on or are intolerant to Hedgehog Inhibitors.
SUBSCRIBE TO BJMO ONCOTALKS SERIES
